Skip to main content
SpringerLink
Log in

Management of Peptic Ulcer Disease

  • Chapter
  • First Online:
Dyspepsia in Clinical Practice

  • 682 Accesses

Abstract

Peptic ulcer disease (PUD) is an important cause of the complex of symptoms known as dyspepsia. Although it can only be found in up to 5% of all upper GI endoscopies performed for investigation of dyspepsia, it can be associated with different complications with the potential for significant morbidity and mortality, such as recurrence, bleeding, perforation, and GI obstruction [1, 2]. The annual incidence rate of peptic ulcer ranges from 0.1% to 0.3% worldwide, but the prevalence of PUD, hospitalization, and surgery rates for uncomplicated ulcers have been in decline in the past few decades [3–6]. These facts are attributed to the better understanding of PUD multifactorial etiology [Helicobacter pylori (H. pylori) infection, nonsteroidal anti-inflammatory drugs (NSAIDs) use and smoking], change in environmental factors (improved food transportation and refrigeration, improved hygiene, socioeconomic conditions, and overall health), and powerful treatment options (antisecretory and antimicrobial drugs) [2, 7]. Peptic ulcers have a variable natural history; they can heal spontaneously but can also have a high recurrence rate ranging between 50% and 80% annually. On the other hand, some can cause complications or remain refractory, despite the antisecretory therapy [8–11].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ford AC, Marwaha A, Lim A, et al. Prevalence of clinically significant endoscopic findings in individuals with and without dyspepsia: systematic review and meta-analysis [abstract]. Gastroenterology. 2009;136 Suppl 1:A488.

    Google Scholar 

  2. el-Serag H, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43:327–33.

    Article  PubMed  CAS  Google Scholar 

  3. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004;159:23–31.

    Article  PubMed  Google Scholar 

  4. Kurata JH. Epidemiology: peptic ulcer risk factors. Semin Gastrointest Dis. 1993;4:2.

    Google Scholar 

  5. Rosenstock SJ, Jorgensen T, Bonnevie O, Andersen LP. Does Helicobacter pylori infection explain all socio-economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adults. Scand J Gastroenterol. 2004;39:823–9.

    Article  PubMed  CAS  Google Scholar 

  6. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29:938–46.

    Article  PubMed  CAS  Google Scholar 

  7. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology. 2007;132:2320–7.

    Article  PubMed  Google Scholar 

  8. Gudmand-Hoyer F, Jensen KB, Krag E, et al. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J. 1978;1:1095.

    Article  PubMed  CAS  Google Scholar 

  9. Current status of maintenance therapy in peptic ulcer disease. The ACG Committee on FDA-Related Matters. Am J Gastroenterol. 1988;83:607–17.

    Google Scholar 

  10. Jorde R, Bostad L, Burhol PG. Asymptomatic gastric ulcer: a follow-up study in patients with previous gastric ulcer disease. Lancet. 1986; 1:119–21.

    Article  PubMed  CAS  Google Scholar 

  11. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther. 1990;4:25–33.

    Article  PubMed  CAS  Google Scholar 

  12. Lam SK. Pathogenesis and pathophysiology of duodenal ulcer. Clin Gastroenterol. 1984;13:447–72.

    PubMed  CAS  Google Scholar 

  13. Malagelada JR, Longstreth GF, Deering TB, et al. Gastric secretion and emptying after ordinary meals in duodenal ulcer. Gastroenterology. 1979;73:989–94.

    Google Scholar 

  14. Merki HS, Fimmel CJ, Walt RP, et al. Pattern of 24 hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut. 1988;29:1583–7.

    Article  PubMed  CAS  Google Scholar 

  15. Samloff IM. Peptic ulcer: the many proteinases of aggression. Gastroenterology. 1989;96:586–95.

    PubMed  CAS  Google Scholar 

  16. Isenberg JI, Selling JA, Hogan DL, Koss MA. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med. 1987;316:374–9.

    Article  PubMed  CAS  Google Scholar 

  17. Miller LJ, Malagelada JR, Longstreth GF, Go VL. Dysfunctions of the stomach with gastric ulceration. Dig Dis Sci. 1980;25:857–64.

    Article  PubMed  CAS  Google Scholar 

  18. McCarthy DM. Sucralfate  Rx. N Engl J Med. 1991;325:1017–25.

    Article  PubMed  CAS  Google Scholar 

  19. Yeomans ND, Svedberg LE, Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Int J Clin Pract. 2006;60:1401–7.

    Article  PubMed  CAS  Google Scholar 

  20. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562–7.

    Article  PubMed  CAS  Google Scholar 

  21. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–50.

    PubMed  CAS  Google Scholar 

  22. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther. 1987;1:239–51.

    Article  PubMed  CAS  Google Scholar 

  23. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345–51.

    PubMed  CAS  Google Scholar 

  24. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol. 1990;12:S54–63.

    Article  PubMed  Google Scholar 

  25. Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci. 1991;36:385–93.

    Article  PubMed  CAS  Google Scholar 

  26. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995;7:661–5.

    PubMed  CAS  Google Scholar 

  27. Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther. 1994;8 Suppl 1:47–52.

    PubMed  Google Scholar 

  28. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.

    Article  PubMed  CAS  Google Scholar 

  29. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.

    Article  PubMed  CAS  Google Scholar 

  30. Tytgat G, Langenberg W, Rauws E, et al. Campylobacter-like organism (CLO) in the human stomach. Gastroenterology. 1985;88:1620.

    Google Scholar 

  31. Marshall BJ, McGechie DB, Rogers PA, et al. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust. 1985;142:439–44.

    PubMed  CAS  Google Scholar 

  32. Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol. 1991;86:1154–7.

    PubMed  CAS  Google Scholar 

  33. Chiorean MV, Locke 3rd GR, Zinsmeister AR, et al. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol. 2002;97:3015–22.

    Article  PubMed  Google Scholar 

  34. Ford AC, Delaney BC, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–55.

    Article  PubMed  Google Scholar 

  35. Buckley M, Culhane A, Drumm B, et al. Guidelines for the management of Helicobacter pylori-related upper gastrointestinal diseases. Irish Helicobacter pylori Study Group. Ir J Med Sci. 1996;165 Suppl 5:1–11.

    PubMed  Google Scholar 

  36. Professional Advisory Panel (CRAG) and Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori eradication therapy in dyspeptic disease: a clinical guideline. 1996.

    Google Scholar 

  37. Lee J, O’Morain C. Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines. Gastroenterology. 1997;113(Suppl):S99–106.

    PubMed  CAS  Google Scholar 

  38. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332:139–42.

    Article  PubMed  CAS  Google Scholar 

  39. Malfertheiner P, Kirchner T, Kist M, et al. Helicobacter pylori eradication and gastric ulcer healing-comparison of three pantoprazole-based triple therapies. BYK Advanced Gastric Ulcer Study Group. Aliment Pharmacol Ther. 2003;17:1125–35.

    Article  PubMed  CAS  Google Scholar 

  40. Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther. 2003;17:111–7.

    Article  PubMed  CAS  Google Scholar 

  41. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071–3.

    Article  PubMed  CAS  Google Scholar 

  42. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet. 2005;365:475–81.

    PubMed  CAS  Google Scholar 

  43. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ. 2005;330:1366.

    Article  PubMed  CAS  Google Scholar 

  44. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.

    Article  PubMed  CAS  Google Scholar 

  45. Simon LS, Hatoum TH, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med. 1996;28:204–10.

    PubMed  CAS  Google Scholar 

  46. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93:2037–46.

    Article  PubMed  CAS  Google Scholar 

  47. Soll AH. Medical treatment of peptic ulcer disease: practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996;275:622–9.

    Article  PubMed  CAS  Google Scholar 

  48. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–17.

    Article  PubMed  Google Scholar 

  49. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27:31–40.

    Article  PubMed  CAS  Google Scholar 

  50. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759–66.

    Article  PubMed  CAS  Google Scholar 

  51. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413–6.

    Article  PubMed  CAS  Google Scholar 

  52. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–55.

    Article  PubMed  CAS  Google Scholar 

  53. Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–92.

    Article  PubMed  CAS  Google Scholar 

  54. Koch M, Dezi A, Ferrario F, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321–32.

    Article  PubMed  CAS  Google Scholar 

  55. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.

    Article  PubMed  Google Scholar 

  56. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719–26.

    Article  PubMed  CAS  Google Scholar 

  57. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:727–34.

    Article  PubMed  CAS  Google Scholar 

  58. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther. 2007;26:1101–11.

    Article  PubMed  CAS  Google Scholar 

  59. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.

    Article  PubMed  CAS  Google Scholar 

  60. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4:130–42.

    Article  PubMed  Google Scholar 

  61. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.

    Article  PubMed  CAS  Google Scholar 

  62. McColl KE, el-Nujimi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut. 1993;34:762–8.

    Article  PubMed  CAS  Google Scholar 

  63. Lanas A, Remacha B, Sainz R, et al. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol. 2000;95:513–9.

    Article  PubMed  CAS  Google Scholar 

  64. Delchier JC, Isal JP, Eriksson S, et al. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut. 1989;30:1173–8.

    Article  PubMed  CAS  Google Scholar 

  65. van Rensburg CJ, Louw JA, Girdwood AH, et al. A trial of lansoprazole in refractory gastric ulcer. Aliment Pharmacol Ther. 1996;10:381–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, University Hospital “Sestre milosrdnice”, Zagreb, Croatia

    Vedran Tomašić

Authors
  1. Marko Duvnjak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vedran Tomašić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vedran Tomašić .

Editor information

Editors and Affiliations

  1. Medical School in Zagreb, University of, Department of Gastroenterology and Hepat, University Hospital “Sestre milosrdnice”, Vinogrdska Str. 29, Zagreb, 10000, Croatia

    Marko Duvnjak

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Duvnjak, M., Tomašić, V. (2011). Management of Peptic Ulcer Disease. In: Duvnjak, M. (eds) Dyspepsia in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1730-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1730-0_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1729-4

  • Online ISBN: 978-1-4419-1730-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation